GBA-targeted therapy
GCase activators and substrate-reduction therapies aimed at GBA-mutation carriers (ambroxol, venglustat, etc.).
State of the art
No update yet for GBA-targeted therapy. An update is a standalone state-of-the-art for the topic — what someone with Parkinson's needs to know about where this approach stands today.
No reader summaries on this topic yet.